Skip to content
Review Open access

Type I interferon in psoriasis: mechanisms and clinical implications

Sep 2026 · Frontiers in Immunology · Vol 17 · 0 citations · 36 references
Medicine

TL;DR

This review presents IFN-I as a stage-dependent and phenotype-specific immune module that links early danger sensing to subsequent inflammatory amplification in psoriasis and discusses the therapeutic significance of tyrosine kinase 2 as a convergence node for IL-23, IL-12, and IFN-I signaling.

Abstract

Psoriasis is a chronic, recurrent, immune-mediated inflammatory skin disease in which the TNF/IL-23/IL-17 axis plays a central role in the maintenance of mature plaques. However, this classical framework does not fully explain the early immune events triggered by skin injury, barrier disruption, infection, and the release of self-nucleic acids. It also does not fully explain selected clinical phenotypes. Type I interferons (IFN-I) are inducible cytokines involved in antiviral defense and danger sensing that may shift from protective immune mediators to pathogenic inflammatory amplifiers in psoriasis-prone skin. Self-nucleic acids released after tissue injury can form immunostimulatory complexes with antimicrobial peptides such as LL37. These complexes activate innate immune responses and induce IFN-I production. This process can promote dendritic-cell maturation and amplify the IL-23/IL-17 inflammatory pathway. This review presents IFN-I as a stage-dependent and phenotype-specific immune module that links early danger sensing to subsequent inflammatory amplification in psoriasis. We focus on the protective role of IFN-I in skin danger responses, LL37-mediated abnormal nucleic acid sensing, multicellular IFN-I skin signatures, the stage-specific integration of IFN-I with the IL-23/IL-17 axis, and clinical contexts with increased IFN-I activity. Moreover, we briefly discuss the therapeutic significance of tyrosine kinase 2 as a convergence node for IL-23, IL-12, and IFN-I signaling. Defining the role of IFN-I across different lesion stages and clinical phenotypes may improve the immunopathological model of psoriasis. It may also provide a basis for disease stratification, response prediction, and individualized therapy.

Read PDF

Similar papers

Review Open access Sep 2026

Inflammatory immune mechanisms underlying the comorbidity of psoriasis and atherosclerosis: clinical implications

This review provides a comprehensive overview of the immunological interactions underlying the psoriasis-atherosclerosis connection and highlights potential therapeutic strategies targeting both cutaneous manifestations and systemic comorbidities.

Wen Xin, Yua Tian, Sha Wang et al. · 0 citations
Review Open access Sep 2026

The active immune role of keratinocytes: from passive targets to key hubs in psoriatic inflammation

Psoriasis is a chronic immune-mediated inflammatory skin disease historically viewed as a disorder of keratinocyte hyperplasia, with subsequent recognition of central immune cell involvement. However, accumulating multi-omics and functional genomic evidence has reshaped this paradigm, positioning keratinocytes not mere...

Yun-Hai Pei · 0 citations
Review Sep 2026

Targeted Immunomodulation in Psoriasis: Emerging progress on biologics and small molecules.

A deeper understanding of psoriasis immunopathogenesis can transform treatment approaches from broad immunosuppression to precision-targeted therapies, and continued development of cytokine- and signaling pathway-specific agents is expected to improve long-term disease control, safety, and personalized patient outcomes...

Rahul Kadiyan, Molly Maheshwari, S. Latha et al. · 0 citations
Review Open access Sep 2026

Interleukin-17 orchestrates psoriasis pathogenesis through canonical and noncanonical signaling pathways and emerging therapeutics

A BSTRACT Psoriasis is a chronic immune-mediated skin disorder, characterized by keratinocyte hyperproliferation and inflammatory cell infiltration. The interleukin-23 (IL-23)/IL-17 axis has been established as a central driver of disease pathogenesis, and biologics targeting this pathway has significantly improv...

Chun-Hua Wang, Lu-Kai Wang, Fu-Ming Tsai · 0 citations
Open access Sep 2026

Targeting epithelial IFN-I signaling restores barrier integrity in anti-TNF refractory Crohn’s disease

It is demonstrated that TNF signaling sustains epithelial IFN-I responses linked to immune regulation and antiviral pathways, establishing a mechanistic connection between chronic TNF signaling and epithelial barrier failure.

Safina Gadeock, Mikayla R. King, D. Polk et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.